康柏西普治疗渗出性年龄相关性黄斑变性的临床观察

目的:分析康柏西普治疗渗出性年龄相关性黄斑变性(age-related macular degeneration,ARMD)的临床疗效.方法:选择2016-01/2017-01我院眼科收治的渗出性ARMD患者21例21眼为研究对象,所有患者均行玻璃体腔内注射康柏西普0.05mL(0.5mg).术后随访3mo,观察术前、术后1wk,1、3mo最佳矫正视力(best corrected visual acuity,BCVA)和黄斑中心凹视网膜厚度(central macular thickness,CMT)的变化.结果:术前和术后1wk,1、3mo患者BCVA分别为0.9±1.4、0.7±1.2、0.5±1.1、0.4±0.9.手术前后患者BCVA具有时间差异性(F=49.12,P<0.001).术后1wk,1mo分别与术前比较差异均无统计学意义(P>0.05);术后3 mo与术前比较,差异有统计学意义(P<0.05).术后3mo,视力改善19眼,视力不变2眼.术前、术后1wk,1、3 mo患者CMT分别为404.25±68.76、354.25±43.12、271.75±32.30、218.30±24.70μm.手术前后患者CMT具有时间差异性(F=2487.45,P<0.001).术后1wk,1、3 mo分别与术前比较,差异均有统计学意义(P<0.001).未发现与药物有关的全身不良反应及眼部并发症.结论:玻璃体腔内注射康柏西普治疗渗出性ARMD疗效显著.

Analysis on Conbercept for exudative age-related macular degeneration

·AIM:To analyze the effect of Conbercept for exudative age-related macular degeneration ( ARMD) .·METHODS: There were 21 eye of 21 patients with exudative ARMD from January 2016 to January 2017 included. All the patients were treated with intravitreal injection of conbercept 0. 5mL (0. 5mg) and followed up for 3mo. The best corrected visual acuity ( BCVA) and central macular thickness (CMT) before and 1wk, 1 and 3mo after treatment were observed.·RESULTS:The BCVA and CMT before and 1wk, 1 and 3mo after treatment were 0. 9±1. 4, 0. 7±1. 2, 0. 5±1. 1 and 0. 4±0. 9. BCVA after treatment were different at different time (F=49. 12, P<0. 001); BCVA at 1wk and 1mo after treatment were not different compared with before treatment ( P> 0. 05 ); that at 3mo were significantly different compared with before (P<0. 05). There were 19 eyes with improved BCVA at 3mo after treatment, unchanged in 2 eyes. CMT before and at 1wk, 1 and 3mo were 404. 25±68. 76, 354. 25±43. 12, 271. 75±32. 30, 218. 30± 24. 70μm. CMT at different time were significantly different (F=2487. 45, P<0. 001);CMT at 1wk, 1 and 3mo were different compared with before treatment ( P <0. 001). There were no severe complications found.·CONCLUSION: Intravitreal injection of conbercept for exudative ARMD is remarkable.